論文

査読有り
2019年8月

The importance of developing therapies targeting the biological spectrum of metastatic disease

CLINICAL & EXPERIMENTAL METASTASIS
  • Andries Zijlstra
  • Ariana Von Lersner
  • Dihua Yu
  • Lucia Borrello
  • Madeleine Oudin
  • Yibin Kang
  • Erik Sahai
  • Barbara Fingleton
  • Ulrike Stein
  • Thomas R. Cox
  • John T. Price
  • Yasumasa Kato
  • Alana L. Welm
  • Julio A. Aguirre-Ghiso
  • 全て表示

36
4
開始ページ
305
終了ページ
309
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s10585-019-09972-3
出版者・発行元
SPRINGER

Great progress has been made in cancer therapeutics. However, metastasis remains the predominant cause of death from cancer. Importantly, metastasis can manifest many years after initial treatment of the primary cancer. This is because cancer cells can remain dormant before forming symptomatic metastasis. An important question is whether metastasis research should focus on the early treatment of metastases, before they are clinically evident ("overt"), or on developing treatments to stop overt metastasis (stage IV cancer). In this commentary we want to clarify why it is important that all avenues of treatment for stage IV patients are developed. Indeed, future treatments are expected to go beyond the mere shrinkage of overt metastases and will include strategies that prevent disseminated tumor cells from emerging from dormancy.

リンク情報
DOI
https://doi.org/10.1007/s10585-019-09972-3
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000474394200002&DestApp=WOS_CPL
ID情報
  • DOI : 10.1007/s10585-019-09972-3
  • ISSN : 0262-0898
  • eISSN : 1573-7276
  • Web of Science ID : WOS:000474394200002

エクスポート
BibTeX RIS